Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

Abstract

Get full access to this article

View all access options for this article.

References

Hsu

Huang

. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. J Immunol Res 2017; 2017: 6940546–6940546.

Topalian

Sznol

McDermott

et al.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020–1030.

Gopalakrishnan

Spencer

Nezi

et al.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359: 97–103.

Imhann

Bonder

Vich Vila

et al.

Proton pump inhibitors affect the gut microbiome. Gut 2016; 65: 740–748.

Röhss

Lind

Wilder-Smith

. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531–539.